Evaluation of physicochemical and functional similarity of a new CHO derived anti-EGFR antibody P-mAb to its reference medicinal product
Source abstract
Abstract
Epidermal growth factor receptor (EGFR) is the primary target for the treatment of colorectal cancer, the third most diagnosed cancer worldwide. In recent years, regulatory changes have facilitated the approval of biosimilars aimed to bring more access to biologics to patients. However, it has also expended the requirements of non-clinical characterisation data using state-of-the-art and orthogonal methodologies to demonstrate similarity between proposed biologic and its reference medicinal product (RMP). The current study was aimed to develop a stable CHO-S cell line producing panitumumab biosimilar candidate, P-mAb, a fully human IgG2 anti-EGFR monoclonal antibody and assess its physicochemical and functional similarity with RMP, Vectibix. The single-cell clone from stably transfected CHO-S cell pools was used for the production of P-mAb. This was followed by purification and comparative physicochemical and biological characterisation of P-mAb and RMP using SDS-PAGE, LC/MS, MALDI, MS/MS, CD spectrometry, DSF, SAXS, ITF, MTT assay and binding affinity. SAXS and MST assays are being used for first time in biosimilarity analysis of therapeutic monoclonal antibody. The results of structural and functional analysis of anti-EGFR P-mAb, produced by stable CHO-S cell line revealed high similarity between P-mAb and RMP, vectibix, thus providing the scientific basis of its potential for therapeutic applications.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Biosimilars and Bioanalytical Methods · Monoclonal and Polyclonal Antibodies Research · Protein purification and stability
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Biochemical Engineering Research and Process Development Centre, CSIR-Institute of Microbial Technology, Chandigarh, India
GNR Advanced Protein Centre, CSIR-Institute of Microbial Technology, Chandigarh, India
References (38)
Show source-provided references
1. DBT. Guidelines on similar biologics: regulatory requirements for marketing authorization in India. 2016. [cited 2019 May 26]:[p. 1–54] https://www.birac.nic.in/webcontent/Guidelines_on_Similar_Biologics_06_10_2017.pdf.
2. 10.1080/19420862.2018.145258010.1080/19420862.2018.1452580 ↗
3. CDER/CBER FDA. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. Guid Ind. 2015. [cited 2021 Jan 26]. https://www.fda.gov/media/135612/download.
4. European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. 2014;44:1–16. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf
5. 10.1080/19420862.2018.155646510.1080/19420862.2018.1556465 ↗
6. 10.1016/j.biotechadv.2011.08.02210.1016/j.biotechadv.2011.08.022 ↗
7. FDA. Biosimilar product information. [cited 2021 Jun 13]. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information.
8. Harston A. How the U.S. compares to Europe on biosimilar approvals and products in the pipeline. 2019. [cited 2020 Apr 10]. https://www.biosimilarsip.com/2019/05/07/how-the-u-s-compares-to-europe-on-biosimilar-approvals-and-products-in-the-pipeline-4/.
9. 10.1007/s00253-011-3758-510.1007/s00253-011-3758-5 ↗
10. Jayapal K, Wlaschin K, Hu W, et al. Recombinant protein therapeutics from CHO cells-20 years and counting. Chem. Eng. Prog. 2007;103:40–47.
11. 10.1016/j.ijpharm.2011.12.03910.1016/j.ijpharm.2011.12.039 ↗
12. 10.1016/j.biotechadv.2015.10.01510.1016/j.biotechadv.2015.10.015 ↗
13. 10.1016/j.ejpb.2011.01.00510.1016/j.ejpb.2011.01.005 ↗
14. 10.3322/caac.2160110.3322/caac.21601 ↗
15. 10.4061/2011/93293210.4061/2011/932932 ↗
16. 10.1016/j.clinthera.2010.03.01210.1016/j.clinthera.2010.03.012 ↗
17. 10.1016/S1040-8428(00)00134-710.1016/S1040-8428(00)00134-7 ↗
18. 10.1056/NEJMoa07183410.1056/NEJMoa071834 ↗
19. 10.1634/theoncologist.12-5-57710.1634/theoncologist.12-5-577 ↗
20. 10.1111/j.1365-2036.2008.03717.x10.1111/j.1365-2036.2008.03717.x ↗
21. 10.1200/JCO.2010.34.124810.1200/JCO.2010.34.1248 ↗
22. 10.1038/227680a010.1038/227680a0 ↗
23. 10.1016/0022-1759(83)90303-410.1016/0022-1759(83)90303-4 ↗
24. 10.1016/j.ejpb.2019.12.00310.1016/j.ejpb.2019.12.003 ↗
25. 10.1002/pro.234010.1002/pro.2340 ↗
26. 10.1016/j.xphs.2019.10.02610.1016/j.xphs.2019.10.026 ↗
27. 10.1002/biot.20080009110.1002/biot.200800091 ↗
28. Dolma K, Nagar J, Sahoo DK, Ashish Tracking urea induced unfolding-refolding of six-domain protein gelsolin by SAXS data analysis. Pharma Innov. J. 2018;7:5–11.
29. 10.1038/s41598-017-06023-310.1038/s41598-017-06023-3 ↗
30. 10.1074/jbc.M70832520010.1074/jbc.M708325200 ↗
31. 10.1080/19420862.2015.100835210.1080/19420862.2015.1008352 ↗
32. 10.1200/JCO.2008.18.078610.1200/JCO.2008.18.0786 ↗
33. 10.1002/adhm.20170011110.1002/adhm.201700111 ↗
34. 10.1016/j.ijrobp.2003.09.09810.1016/j.ijrobp.2003.09.098 ↗
35. Yang XD, Jia XC, Corvalan JRF, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 1999;59:1236–1243.
36. 10.1158/1078-0432.CCR-07-006510.1158/1078-0432.CCR-07-0065 ↗
37. 10.1080/19420862.2018.143397610.1080/19420862.2018.1433976 ↗
38. 10.1038/ncomms109310.1038/ncomms1093 ↗